



Supplemental Fig. S5. The proportion of end-stage kidney disease events in the placebo groups of dipeptidyl peptidase-4 inhibitor (DPP-4i) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) studies using a fixed effect model. CI, confidence interval; EXAMINE, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; SAVOR-TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53; TECOS, Trial Evaluating Cardiovascular Outcomes with Sitagliptin; CARMELINA, Cardiovascular and Renal Microvascular Outcome Study with Linagliptin; EMPA-REG, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose; CANVAS, Canagliflozin Cardiovascular Assessment Study; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; DECLARE-TIMI 58, Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58.